Artios

To add a bio or update company history, please click update information.

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Artios

Life Sciences
Cambridge, United Kingdom
£90m
artios.com
Update Information

More venture news

Big Picture Bio
18 Sept 2026
Big Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences
Eterna Regeneratives
16 Sept 2026
Eterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
Magnitude Biosciences
15 Sept 2026
Magnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms
EquityLife Sciences

Artios

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

More venture news

Big Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies

Eterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair

Magnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms